Zhejiang Cheng Yi Pharmaceutical Co Ltd

Chengyi Pharmaceutical released its 2026 interim report. The company's total operating revenue was 432 million yuan, and net profit attributable to the parent company was 94.8687 million yuan, a decrease of 15.61% compared with the same period last year. Net cash inflow from operating activities was 141 million yuan, down 0.28% year-on-year. The company's latest asset-liability ratio was 18.49%, gross margin was 70.83%, ROE was 6.68%, and diluted earnings per share was 0.21 yuan, down 16.00% year-on-year. The number of shareholders was 20,700, and the top ten shareholders held 38.49% of the total share capital.

Chengyi Pharmaceutical released its 2026 half-year report. First-half net profit attributable to the parent was 94.87 million yuan, down 15.6% year on year. Operating revenue was 432 million yuan, up 3.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 92.45 million yuan, down 16.8% year on year. Net operating cash flow was 141 million yuan, down 0.3% year on year. Earnings per share were 0.207 yuan. In the second quarter, operating revenue was 231 million yuan, down 0.1% year on year, and net profit attributable to the parent was 50.58 million yuan, down 24.1% year on year. As of the end of the second quarter, total assets were 1.751 billion yuan, up 2.9% from the end of the previous year, and net assets attributable to the parent were 1.419 billion yuan, up 2.1%. The company said the pharmaceutical industry is under overall pressure but market size is still growing. Its core glucosamine product business showed outstanding performance in market expansion and self-sufficiency in raw materials, and its health product Yuzhixin fish oil soft capsules received approval. The company is also responding to challenges by strengthening in-house production of active pharmaceutical ingredients, optimizing channels, disposing of loss-making subsidiaries, and implementing an employee stock ownership plan.